Sridhar Allam
Transplant Surgery · McAllen, TXNPI 1700061819
Payments from drug & device makers
Across 542 payments — averaging $722.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$123K
- Calliditas Therapeutics US Inc.$84K
- AstraZeneca$73K
- Veloxis Pharmaceuticals, Inc.$59K
- Sanofi-aventis U.S. LLC$35K
- Amicus Therapeutics, Inc.$8K
- plus $10K from 26 others
What the payments were for
- Consulting fees$54,05514%
- Speaking & faculty fees$258,13266%
- Travel & lodging$66,92617%
- Food & beverage$12,2603%
- Education$2290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 156 | $122,878 |
| Calliditas Therapeutics US Inc. | 100 | $83,921 |
| AstraZeneca(2 entities) | 102 | $73,169 |
| Veloxis Pharmaceuticals, Inc. | 74 | $58,511 |
| Sanofi-aventis U.S. LLC | 32 | $34,592 |
| Amicus Therapeutics, Inc. | 8 | $8,252 |
| Sanofi | 3 | $3,200 |
| Mallinckrodt Enterprises LLC | 3 | $2,652 |
| Invivyd Inc | 2 | $1,908 |
| Amgen(2 entities) | 19 | $429 |
| Travere Therapeutics, Inc. | 3 | $277 |
| Melinta Therapeutics, LLC | 2 | $250 |
| Merck | 5 | $250 |
| Gilead | 2 | $246 |
| Astellas Pharma US Inc | 3 | $156 |
| Bayer | 3 | $151 |
| E.r. Squibb & Sons, L.L.C. | 2 | $130 |
| AbbVie | 1 | $115 |
| Mallinckrodt Hospital Products Inc. | 1 | $98 |
| Vifor Pharma, Inc. | 3 | $78 |
| GSK | 4 | $58 |
| Paratek Pharmaceuticals, Inc. | 2 | $48 |
| OPKO Pharmaceuticals, LLC | 2 | $36 |
| Novo Nordisk | 2 | $33 |
| Akebia Therapeutics Inc | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Novartis | 1 | $19 |
| Abbott | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$391,602 in reported general payments places this provider in the 95th percentile of 70 transplant surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GalafoldMigalastat Hcl | 12 | $353,716 |
| EliquisApixaban | 49 | $51,040 |
| MounjaroTirzepatide | 35 | $41,602 |
| Envarsus XrTacrolimus | 41 | $40,680 |
| Valganciclovir Hcl | 179 | $31,665 |
| JanuviaSitagliptin Phosphate | 34 | $25,829 |
| OzempicSemaglutide | 18 | $22,533 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $18,514 |
| Atovaquone | 25 | $16,008 |
| Humalog Kwikpen U-100Insulin Lispro | 67 | $13,765 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $10,634 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $10,209 |
| Mycophenolic AcidMycophenolate Sodium | 49 | $9,933 |
| Tacrolimus | 62 | $7,645 |
| Nifedipine ErNifedipine | 328 | $7,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amicus Therapeutics, Inc.Galafold | $8,252 | $353,71612 claims |
| MerckJanuvia | $250 | $25,82934 claims |
| Novo NordiskOzempic | $33 | $22,53318 claims |
| AstraZenecaLokelma | $73,169 | $10,63412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 70 transplant surgery providers in Texas.
Other transplant surgery in McAllen
- Ashraf ReyadMcAllen$1K
- Jose Valdes BracamontesMcAllen$1K
- Eduardo FernandesMcAllen$442
- Philip ThomasMcAllen$338
- Rafik GhobrialHouston$1M
- Ahmed GaberHouston$769K
- Constance MobleyHouston$102K
- Goran KlintmalmDallas$88K
- David HallHouston$43K
- Colleen JaySan Antonio$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.